1535-76-8 Usage
General Description
4-Amino-2-(trifluoromethyl)phenol is an organic compound with the chemical formula C7H6F3NO. It is a white crystalline powder that is commonly used as a raw material in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. This chemical has applications in the production of dyes, pigments, and polymers, as well as in the manufacturing of personal care products and cosmetics. It is also used as an intermediate in the manufacture of UV absorbers and antioxidants. Additionally, 4-amino-2-(trifluoromethyl)phenol is utilized as a reagent in organic chemistry and is known for its potential biological activity. However, it is important to handle this chemical with care, as it may be harmful if ingested, inhaled, or in contact with the skin, and should be stored and used in accordance with proper safety protocols.
Check Digit Verification of cas no
The CAS Registry Mumber 1535-76-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,5,3 and 5 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1535-76:
(6*1)+(5*5)+(4*3)+(3*5)+(2*7)+(1*6)=78
78 % 10 = 8
So 1535-76-8 is a valid CAS Registry Number.
1535-76-8Relevant articles and documents
Photochemistry of flutamide in various media: Investigation of the reaction mechanism as revealed by external magnetic field effects on product yields
Udagawa, Chikako,Fukuyoshi, Shuichi,Morimoto, Shotaro,Tanimoto, Yoshifumi,Nakagaki, Ryoichi
, p. 57 - 63 (2011)
Photochemistry of an anticancer drug flutamide, 2-methyl-N-[4-nitro-3- (trifluoromethyl) phenyl] propanamide has been investigated in various media in the absence and presence of 0.1 T magnetic field. On photoexcitation flutamide gives rise to a phenol de
COMPOUNDS USEFUL AS RETINOID-RELATED ORPHAN RECEPTOR GAMMA MODULATORS
-
, (2012/08/08)
Disclosed are retinoid-related orphan receptor gamma (RORγ) modulators of Formula (I) and their use in the treatment of diseases mediated by RORγ, wherein the radicals have the meanings as defined in the invention.